The Improved Anticancer Effects of Bortezomib-loaded Hollow Mesoporous Silica Nanospheres on Lymphoma Development

Overview

Journal Aging (Albany NY)

Specialty Geriatrics

Date 2020 Dec 8

PMID 33290262

Citations 2

Authors

Jie Shen

Ruihuan Wang

Qing Wang

Minjuan Zhang

Chunyan Liu

Zhenxia Tao

Guohong Su

Affiliations

Soon will be listed here.

Abstract

As the first clinical proteasome inhibitor, Bortezomib (BTZ) has been reported to improve the outcome of lymphoma. However, due to the unstable property, low bioavailability, and hydrophobic properties of BTZ, it is needed to develop effective drug delivery systems to deliver BTZ into targeted cells or organs. Here we developed a bortezomib (BTZ)-loaded HMSNs (BTZ@HMSNs) system, which can sustain the release of BTZ in targeted tissues. assays showed that BTZ@HMSNs limited cell proliferation and augmented apoptosis of lymphoma SNK-1 cells. Moreover, BTZ@HMSNs significantly diminished migration and invasion of SNK-1 cells as compared with BTZ. In contrast to the upregulation of SHP-1, BTZ@HMSNs decreased the mRNA levels of , , and , which elicit oncogenic role in lymphoma development. Importantly, lymphoma mice model showed that BTZ@HMSNs significantly activated p53 signaling and reduced tumor volume and weight compared with free BTZ. Our data thus demonstrate that BTZ@HMSNs manifests improved tumor-suppressing effect and compared to free BTZ. We believe that HMSNs is a promising strategy for delivering therapeutic agents for cancer treatment.

Citing Articles

A meta-analysis of risk factors for cardiovascular adverse events with anthracycline based chemotherapy in lymphoma patients.

Dai B, Xu J, Wang B BMC Cancer. 2025; 25(1):162.

PMID: 39875837 PMC: 11773729. DOI: 10.1186/s12885-024-13305-3.

Macrophage membrane‒biomimetic nanoparticles target inflammatory microenvironment for epilepsy treatment.

Geng C, Ren X, Cao P, Chu X, Wei P, Liu Q Theranostics. 2024; 14(17):6652-6670.

PMID: 39479447 PMC: 11519803. DOI: 10.7150/thno.99260.

ATRP-based synthesis of a pH-sensitive amphiphilic block polymer and its self-assembled micelles with hollow mesoporous silica as DOX carriers for controlled drug release.

Qi X, Yan H, Li Y RSC Adv. 2022; 11(48):29986-29996.

PMID: 35480284 PMC: 9040921. DOI: 10.1039/d1ra03899k.

References

Zhang Y, Ang C, Li M, Tan S, Qu Q, Luo Z . Polymer-Coated Hollow Mesoporous Silica Nanoparticles for Triple-Responsive Drug Delivery. ACS Appl Mater Interfaces. 2015; 7(32):18179-87. DOI: 10.1021/acsami.5b05893. View

Chen D, Frezza M, Schmitt S, Kanwar J, Dou Q . Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives. Curr Cancer Drug Targets. 2011; 11(3):239-53. PMC: 3306611. DOI: 10.2174/156800911794519752. View

Yazbeck V, Shafer D, Perkins E, Coppola D, Sokol L, Richards K . A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-cell Lymphoma. Clin Lymphoma Myeloma Leuk. 2018; 18(9):569-575.e1. PMC: 11673799. DOI: 10.1016/j.clml.2018.05.023. View

Fang X, Chen C, Liu Z, Liu P, Zheng N . A cationic surfactant assisted selective etching strategy to hollow mesoporous silica spheres. Nanoscale. 2011; 3(4):1632-9. DOI: 10.1039/c0nr00893a. View

Taniguchi K, Karin M . NF-κB, inflammation, immunity and cancer: coming of age. Nat Rev Immunol. 2018; 18(5):309-324. DOI: 10.1038/nri.2017.142. View

Ichim G, Tait S . A fate worse than death: apoptosis as an oncogenic process. Nat Rev Cancer. 2016; 16(8):539-48. DOI: 10.1038/nrc.2016.58. View

Hatok J, Racay P . Bcl-2 family proteins: master regulators of cell survival. Biomol Concepts. 2016; 7(4):259-70. DOI: 10.1515/bmc-2016-0015. View

Dreyling M, Campo E, Hermine O, Jerkeman M, Le Gouill S, Rule S . Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017; 28(suppl_4):iv62-iv71. DOI: 10.1093/annonc/mdx223. View

Till B, Li H, Bernstein S, Fisher R, Burack W, Rimsza L . Phase II trial of R-CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: SWOG S0601. Br J Haematol. 2015; 172(2):208-18. PMC: 4710555. DOI: 10.1111/bjh.13818. View

10.

Kozlowski M, Larose L, Lee F, Le D, Rottapel R, Siminovitch K . SHP-1 binds and negatively modulates the c-Kit receptor by interaction with tyrosine 569 in the c-Kit juxtamembrane domain. Mol Cell Biol. 1998; 18(4):2089-99. PMC: 121439. DOI: 10.1128/MCB.18.4.2089. View

11.

Castillo J, Reagan J, Sikov W, Winer E . Bortezomib in combination with infusional dose-adjusted EPOCH for the treatment of plasmablastic lymphoma. Br J Haematol. 2015; 169(3):352-5. DOI: 10.1111/bjh.13300. View

12.

Paramore A, Frantz S . Bortezomib. Nat Rev Drug Discov. 2003; 2(8):611-2. DOI: 10.1038/nrd1159. View

13.

Shen J, Song G, An M, Li X, Wu N, Ruan K . The use of hollow mesoporous silica nanospheres to encapsulate bortezomib and improve efficacy for non-small cell lung cancer therapy. Biomaterials. 2013; 35(1):316-26. DOI: 10.1016/j.biomaterials.2013.09.098. View

14.

Robak T, Huang H, Jin J, Zhu J, Liu T, Samoilova O . Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma. N Engl J Med. 2015; 372(10):944-53. DOI: 10.1056/NEJMoa1412096. View

15.

Lub S, Maes K, Menu E, de Bruyne E, Vanderkerken K, Van Valckenborgh E . Novel strategies to target the ubiquitin proteasome system in multiple myeloma. Oncotarget. 2015; 7(6):6521-37. PMC: 4872730. DOI: 10.18632/oncotarget.6658. View

16.

Brigger I, Dubernet C, Couvreur P . Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev. 2002; 54(5):631-51. DOI: 10.1016/s0169-409x(02)00044-3. View

17.

Ramasamy T, Ruttala H, Gupta B, Poudel B, Choi H, Yong C . Smart chemistry-based nanosized drug delivery systems for systemic applications: A comprehensive review. J Control Release. 2017; 258:226-253. DOI: 10.1016/j.jconrel.2017.04.043. View

18.

Rajoria S, Rani S, Chaudhari D, Jain S, Gupta U . Glycine-Poly-L-Lactic Acid Copolymeric Nanoparticles for the Efficient Delivery of Bortezomib. Pharm Res. 2019; 36(11):160. DOI: 10.1007/s11095-019-2686-4. View

19.

Ramasamy T, Ruttala H, Kaliraj K, Poudel K, Jin S, Choi H . Polypeptide Derivative of Metformin with the Combined Advantage of a Gene Carrier and Anticancer Activity. ACS Biomater Sci Eng. 2021; 5(10):5159-5168. DOI: 10.1021/acsbiomaterials.9b00982. View

20.

Wu C, Sun M, Liu L, Zhou G . The function of the protein tyrosine phosphatase SHP-1 in cancer. Gene. 2003; 306:1-12. DOI: 10.1016/s0378-1119(03)00400-1. View